| Similar Articles |
|---|
 |
The Motley Fool
May 3, 2011
Brian Orelli |
Teva's Branded-Drug Binge For a company that's a generic-drug maker, Teva Pharmaceuticals sure does like its branded drugs. Despite the warts the company is ponying up $6.2 billion to buy Cephalon.   |
The Motley Fool
February 14, 2008
Brian Lawler |
Waking Cephalon Up Specialty pharma Cephalon presents its 2007 financial results and 2008 guidance. |
Chemistry World
June 1, 2015
Phillip Broadwith |
Teva fined $1.2bn in pay-for-delay case Israeli firm Teva has reached a settlement with the US Federal Trade Commission over allegations of cutting illegal deals with generic drugmakers to stifle competition for sleep disorder drug Provigil (modafinil). |
The Motley Fool
November 4, 2004
Charly Travers |
Drug Growth Screeching to a Halt Given the threat of generics to not-so-small drug company Cephalon's product line, the acquisition of CIMA labs in August of this year could turn out to be quite important. |
The Motley Fool
September 30, 2011
Brian Orelli |
When You Need More Than Just a Low-Margin Business Teva Pharmaceuticals, arguably the largest generic-drug maker, can use economies of scale more easily than smaller companies like Watson Pharmaceuticals or Par Pharmaceutical, but it's still pushing further into branded drugs. |
The Motley Fool
February 15, 2005
Stephen D. Simpson |
Teva: Scourge of the Drug World? The world's largest generics maker continues to post strong growth by bedeviling Big Pharma. |
The Motley Fool
August 19, 2004
Charly Travers |
1 Pill for Sleep, Attention Ailments? Cephalon gets some good news about its drug PROVIGIL. |
The Motley Fool
June 30, 2005
Brian Gorman |
Teva's Non-Generic Side The drug company is working hard to cement its position in the market for multiple sclerosis meds. Investors, take note. |
Chemistry World
April 13, 2015
Emma Stoye |
Generics giant Mylan offers $30 billion for Perrigo Generics manufacturer Mylan has made an unsolicited, public offer to buy Ireland-based rival Perrigo for $205 per share. |
The Motley Fool
May 2, 2011
Arundhati Parmar |
Teva pays $6.8B to buy Cephalon, including Minnesota's CIMA Labs Teva diversifies. |
Chemistry World
December 8, 2015
Phillip Broadwith |
Perrigo nabs US rights to AZ Crohn's drug Irish drug maker Perrigo has fended off a hostile takeover bid from rival Mylan, and agreed to buy the US distribution rights to AstraZeneca's gastroenterology drug Entocort (budesonide). |
The Motley Fool
May 12, 2011
Brian Orelli |
Teva's Mixed Bag Diversification sure helps. |
The Motley Fool
April 13, 2010
Brian Orelli |
Teva Gets Less Generic The generic-drug maker makes a major push into branded-drug development. |
The Motley Fool
August 1, 2005
Stephen D. Simpson |
Teva: Built to Last? Israeli generics giant Teva Pharmaceuticals is a high-quality company trading at a level that should still provide patient investors with solid long-term performance. |
The Motley Fool
February 16, 2007
Brian Lawler |
Cephalon's Supercharged Growth The pharmaceutical announces fourth-quarter results and updates 2007 guidance. Investors, take note. |
Pharmaceutical Executive
October 1, 2010 |
Taking a Less-Generic Route to Generics A leading pharmaceutical industry player speaks out on what is fueling success in the sector. |
BusinessWeek
November 1, 2004
Amy Barrett |
This Pep Pill is Pushing Its Luck Half of Provigil prescriptions may be for "off-label" uses. Did its maker cross the line? But Cephalon is hardly the only drugmaker in the spotlight. |
The Motley Fool
February 28, 2006
Stephen D. Simpson |
Still Waiting for Teva to Stumble This leading Israeli generics firm hasn't seen a stock pullback of any consequence since mid- to late 2004. And while fourth-quarter results weren't fabulous, they were good enough given the circumstances |
Pharmaceutical Executive
October 1, 2006
Joanna Breitstein |
"I Pray for the Welfare of Your Company..." Big Pharma's drugs fill Teva Pharmaceutical's pipeline. CEO Israel Makov says he's not the enemy. To prove it, he offers lessons in survival. |
Chemistry World
April 1, 2015
Emma Stoye |
Teva buys Auspex Pharmaceuticals for $3.2bn In a bid to strengthen its position in central nervous system R&D, one of its core therapeutic areas, generics giant Teva is set to acquire US-based biotech firm Auspex Pharmaceuticals. |
The Motley Fool
April 2, 2007
Brian Lawler |
FDA Keeps Cephalon Waiting The FDA issues Cephalon an approvable letter for one of its drugs. Investors, take note. |
The Motley Fool
August 8, 2006
Stephen D. Simpson |
Nothing Generic About Teva's Performance Once again, buying this this Israeli generics giant on dips returns a tidy profit. |
The Motley Fool
November 8, 2006
Brian Lawler |
Teva Is Rolling in Cash Again Investors, the bottom line is that with 13 proprietary drugs in phase 2 trials or later for some very large indications, plus 144 applications to sell generic versions of branded drugs waiting at the FDA, Teva's near-term future is strong. |
The Motley Fool
November 9, 2007
Brian Lawler |
Cephalon Wheels and Deals Sales and net income fall in the third quarter, but increased guidance sends shares of the drugmaker higher. |
The Motley Fool
July 27, 2010
Brian Orelli |
Branded? Generic? They're Both Doing Great! Teva Pharmaceuticals registers strong growth on both fronts. |
The Motley Fool
April 11, 2011
Jim Mueller |
A Missed Opportunity Cephalon showed up on my screen as a potential buy, but others liked it, too. |
The Motley Fool
November 6, 2006
Brian Lawler |
No Worries About Cephalon This solid biopharma ups its yearly guidance -- for the fourth time. Investors, take note. |
The Motley Fool
July 25, 2005
Stephen D. Simpson |
Teva Tries to Buy Back the Top Spot $7.4 billion later, Teva Pharmaceuticals is poised to become the largest generics company in the world once again. Investors, take note. |
The Motley Fool
September 20, 2007
Brian Orelli |
Teva's Disappointing Phase 2 Results Teva's lupus drug fails to meet its primary endpoint in its phase 2 trial. Investors, take note. |
The Motley Fool
April 27, 2007
Brian Lawler |
Cephalon's Earnings Surprise The drugmaker raises its earnings guidance for the year. With no serious competition for its lead compounds in the near term, investors should take a look at the well-run pharma. |
The Motley Fool
May 7, 2008
Brian Orelli |
Teva's on a Tear The generic-drug maker can't be stopped. |
The Motley Fool
January 31, 2011
Brian Orelli |
Time to Buy Into Stem Cells? New developments bring this analyst a step closer to opening his wallet. |
The Motley Fool
November 27, 2006
Brian Lawler |
Teva and Pfizer Make Up The companies decide to play nice over generic versions of two of Pfizer's drugs. |
The Motley Fool
March 31, 2008
Rich Duprey |
Teva's Tough Pill to Swallow Eisai wins a preliminary injunction against Teva's generic Alzheimer's treatment. |
The Motley Fool
June 26, 2006
Stephen D. Simpson |
Is Novartis the Future of Generics? Merck's recent pricing action might just be the beginning of the end of generics as we know them. Investors, take note. |
Chemistry World
July 29, 2015
Katrina Megget |
Allergan steps away from generics with sale to Teva In something of a surprise move, Allergan has committed to selling its generics business to Israeli generics giant Teva for $40.5 billion, despite having no prior plans to sell. |
The Motley Fool
November 15, 2011
Brian Orelli |
When Giving Up Is a Good Move in Biotech Geron calls it quits with stem cells. |
The Motley Fool
March 30, 2010
Brian Orelli |
FDA Lags, Investors Flee Cephalon gets no love from the FDA. The agency failed to expand Cephalon's Nuvigil for the treatment of jet lag. |
The Motley Fool
July 14, 2008
Brian Orelli |
Teva Gets a Taste of Its Own Medicine Momenta Pharmaceuticals and Novartis are challenging the patents on Teva Pharmaceutical's blockbuster multiple sclerosis drug Copaxone. |
The Motley Fool
November 20, 2008
Brian Orelli |
Double Trouble for AstraZeneca A double dose of bad news for AstraZeneca. Current revenue is vanishing, and potential revenue is failing to materialize. |
The Motley Fool
May 5, 2010
Brian Orelli |
Teva's Double-Edged Sword Nice quarter, but where will future growth come from? |
Chemistry World
September 10, 2015
Katrina Megget |
Merger fever sweeps pharma Cheap financing, among other factors, is allowing companies to stock their drug pipelines through acquisitions |
The Motley Fool
August 3, 2007
Brian Lawler |
Cephalon's Case of Spending Blues Cephalon announces its second-quarter financial results. Sales were up, so why is the share price down? Perhaps escalating SG&A expenses are the culprit. |
The Motley Fool
February 17, 2010
Brian Orelli |
This Is Not Your Generic Cash Production Teva's generating cash and knows how to use it. |
The Motley Fool
March 30, 2011
Brian Orelli |
Valeant Vultures Will Cephalon manage to rebuff Valeant's advances? |
BusinessWeek
November 3, 2003
Diane Brady |
Biotech: Teva's Next Triumph? The Israeli maker of generics wants a piece of the fast-growing bio-drug market. |
Chemistry World
May 1, 2015
Rebecca Trager |
Generics firms in three-way takeover battle US-based Mylan is gunning for Irish rival Perrigo, but the deal is overshadowed by a bid for Mylan itself from Israel's powerhouse Teva. |
The Motley Fool
February 17, 2006
Brian Gorman |
Enthusiasm for Cephalon The company seems to be counting on a strong showing for a new drug, but for investors, it may pay to be cautious. |
The Motley Fool
October 13, 2009
Dave Mock |
A Big Upgrade for Teva Pharmaceutical This bullish call comes from more than just one analyst. |
The Motley Fool
April 1, 2008
Brian Lawler |
Cephalon Plays "Let's Make a Deal" Cephalon acquires an oncology drug on the cheap from tiny Acusphere. |
